

## **Figure e-1. MRI lesion number outcomes at 2 years – results of primary and sensitivity analyses**

Sensitivity analyses, illustrating outcomes based on all observed data alongside those based on observed data prior to starting alternative MS medication.


Abbreviations: BID = twice daily; DMF = delayed-release dimethyl fumarate (also known as gastro-resistant DMF); GA = glatiramer acetate; Gd+ = gadolinium-enhancing; ITT = intent-to-treat;

MS = multiple sclerosis; OR = odds ratio; TID = three times daily.

<sup>a</sup>Ratios shown are lesion mean ratios, from baseline to 2 years; 95% CI and *p*-value for comparison between active and placebo groups, based on negative binomial regression, adjusted for region and baseline lesion volume.

<sup>b</sup>Primary MRI analyses – excluded observed data obtained after switch to alternative MS medications. Missing data prior to alternative MS medications and visits after switch are imputed using the constant rate assumption.

<sup>c</sup>Odds ratio, 95% CI and *p*-values for comparison between active and placebo groups at 2 years, based on ordinal logistic regression, adjusted for region and baseline number of Gd+ lesions.



<sup>a</sup>DMF, delayed-release DMF (also known as gastro-resistant DMF)